Iterum Therapeutics PLC represents a commitment to developing innovative and effective therapies to combat serious infections. As a pharmaceutical company, Iterum Therapeutics is driven by a mission to address unmet medical needs and improve patient outcomes. Their corporate philosophy revolves around rigorous research, scientific expertise, and a patient-centric approach. With a focus on developing novel antibiotics, Iterum Therapeutics aims to provide treatment options for challenging infectious diseases. By leveraging their understanding of bacterial resistance and drug development, Iterum Therapeutics PLC strives to make a positive impact on global healthcare.

Iterum Therapeutics PLC is primarily present in multiple countries and regions worldwide. These include the United States, where the company is headquartered, as well as other key regions such as Europe and Asia. With its global presence, Iterum Therapeutics PLC aims to cater to a diverse patient population and expand its reach in the pharmaceutical market. Notably, the company's commitment to improving patient outcomes and developing innovative therapeutic solutions has led to its presence in various healthcare systems and markets across different countries and regions.

Iterum Therapeutics PLC has achieved several significant milestones in its journey. The company successfully completed its initial public offering, raising substantial funds to support its research and development efforts. Iterum Therapeutics PLC also obtained Fast Track designation from the U.S. Food and Drug Administration for its novel antibiotic, sulopenem, which targets multi-drug resistant pathogens. Furthermore, the company initiated its phase 3 clinical trials for sulopenem in complicated urinary tract infections. Iterum Therapeutics PLC continues to advance its pipeline and collaborate with industry leaders, aiming to provide effective treatment options for infectious diseases.

Iterum Therapeutics PLC is a pharmaceutical company focused on developing innovative anti-infectives. Founded in 2015, Iterum is based in Dublin, Ireland. The company aims to address the growing issue of antibiotic-resistant infections by discovering and developing new therapeutic options. Iterum Therapeutics PLC primarily focuses on developing new treatments for patients suffering from urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. With a commitment to improving global public health, Iterum Therapeutics PLC dedicates its efforts to advance the field of anti-infectives and provide better treatment options for patients worldwide.

The main competitors of Iterum Therapeutics PLC in the market include pharmaceutical companies such as Pfizer Inc., Merck & Co., and Johnson & Johnson. These companies compete with Iterum Therapeutics PLC in the development and commercialization of innovative therapies and drugs. It is essential for Iterum Therapeutics PLC to strategically position itself among these established competitors in order to capture a significant market share and gain a competitive edge.

Iterum Therapeutics PLC primarily operates in the pharmaceutical industry. As a biotechnology company, Iterum Therapeutics is focused on developing and commercializing innovative therapeutics to address significant unmet medical needs. Its primary area of expertise lies in developing novel antibiotics to combat multi-drug resistant pathogens, with a particular focus on urinary tract infections. Iterum Therapeutics PLC is dedicated to improving patient outcomes and advancing the field of infectious disease treatment through its research and development efforts.

Iterum Therapeutics PLC operates as a clinical-stage pharmaceutical company. The company focuses on the development and commercialization of innovative anti-infectives for patients suffering from serious and life-threatening infections. Iterum Therapeutics PLC aims to address the growing concern of antimicrobial resistance by developing novel antibiotics. Through its research, development, and partnership collaborations, the company strives to provide effective treatment options for infections that are resistant to existing therapies. Iterum Therapeutics PLC's business model revolves around developing and bringing to market new antibiotics to improve patient outcomes in the face of increasing antibiotic resistance.

Коефициентът на цена спрямо печалбата (КЦП) на Iterum Therapeutics е -0,99.

Коефициентът на цена към оборот (KUV) на Iterum Therapeutics е 0.

AlleAktien качественият резултат за Iterum Therapeutics е 3/10.

Приходите не могат да бъдат изчислени в момента за Iterum Therapeutics.

очаквана Iterum Therapeutics печалба е -13,85 млн. USD.

Iterum Therapeutics PLC is a company that specializes in the discovery, development, and commercialization of antibiotics. It was founded in 2015 and is headquartered in Dublin, Ireland. The company is considered one of the most innovative in drug research and aims to develop antibiotics that are effective against the increasing resistance of bacteria. Iterum Therapeutics has a broad portfolio of products in the pipeline targeting the treatment of infections caused by various types of bacteria. The company has focused on the development of macrolide antibiotics, known for their effectiveness against microorganisms. One of Iterum Therapeutics' most important products is the antibiotic Sulopenem. Sulopenem is a third-generation broad-spectrum antibiotic effective against bacteria that have become resistant to other antibiotics. The medication is currently being tested in clinical trials as a treatment for various infections, including urinary tract infections, abdominal infections, and pneumonia. In addition to Sulopenem, Iterum Therapeutics also has other antibiotics in the pipeline, including Sulopenem oral tablets suitable for the treatment of urinary tract infections caused by gram-positive, gram-negative, and anaerobic bacteria. The company has also entered into an agreement with US biotechnology company Cidara Therapeutics, in which Iterum acquired the global rights to Rezafungin, a broad-spectrum antifungal. Rezafungin is currently undergoing phase III clinical trials for the treatment of fungal infections in patients with invasive Candida infections and aspergillosis. Iterum Therapeutics is also pursuing expansion into the European market and is in the process of applying for European approval for Sulopenem. The company plans to market Sulopenem in other countries, including Asia. The business model of Iterum Therapeutics is based on the discovery and development of new antibiotics effective against the increasing resistance of bacteria. The company follows a strict selection process for potential candidates and utilizes modern technologies and scientific methods to identify potential drug candidates. Iterum works closely with leading academic institutions and research partners to integrate innovative concepts into the development of new antibiotics. Iterum Therapeutics also has a comprehensive marketing strategy aimed at maximizing the potential of antibiotics and meeting the needs of patients and healthcare facilities. The company aims to treat a wide range of infections to meet market demand and increase the commercialization of antibiotics. In summary, Iterum Therapeutics is a significant company in drug research and antibiotic development that focuses on combating bacterial resistance. The company has a strong portfolio of products in the pipeline and has an experienced management team driving the company's vision.

Iterum Therapeutics разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Iterum Therapeutics в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Iterum Therapeutics е IE00BF3W0Q35.

WKN на Iterum Therapeutics е A2JMZP.

Тикерът на Iterum Therapeutics е ITRM.

През последните 12 месеца Iterum Therapeutics изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Iterum Therapeutics да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Iterum Therapeutics в момента е .

Iterum Therapeutics изплаща дивидент на тримесечие. Той се разпределя в месеците .

Iterum Therapeutics платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Iterum Therapeutics се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Iterum Therapeutics на 29.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 29.09.2024 г..

Последното дивидентно плащане беше извършено на 29.09.2024 г..

През година 2023 Iterum Therapeutics изплати 0 USD под формата на дивиденти.

Дивидентите от Iterum Therapeutics се изплащат в USD.